Hoffmann-La Roche - Recruiting 18 years to 65 years. - A Single Blind Phase IV Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose Tocilizumab Treatment in Healthy Subjects.
AstraZeneca - Recruiting 18 years to 55 years. - A Phase I, Randomized, Placebo-controlled, Single Center Study to Assess the Safety, Tolerability, and Pharmacokinetic of AZD0914 After Oral Administration of Single Doses or Multiple Doses Over 24 Hours and to Assess the Effect of Food in Healthy Adult Volunteers.
Hoffmann-La Roche - Recruiting 21 years to 65 years. - A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6864018 FOLLOWING ORAL ADMINISTRATION IN ASIAN HEALTHY SUBJECTS.
Genentech - Recruiting 18 years to 45 years. - A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study in Healthy Volunteers to Evaluate the Efficacy and Safety of MHAA4549A in an Influenza Challenge Model.
Hoffmann-La Roche - Recruiting 18 years to 65 years. - A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects.
Hoffmann-La Roche - Recruiting 18 years to 55 years. - An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects.
Hoffmann-La Roche - Recruiting 18 years to 65 years. - A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacodynamics and the Effect of Food on the Pharmacokinetics of RO6870868.
Hoffmann-La Roche - Recruiting 18 years to 64 years. - A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects..
Pfizer - Recruiting 18 years to 55 years. - A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects.
Peking University Third Hospital - Recruiting 20 years to 45 years. - A Single-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study to Assess the QT/QTc Interval After Administration of Single Oral Dose of 400mg Moxifloxacin in Healthy Chinese Subjects.
Diakron Pharmaceuticals - Recruiting 18 years to 50 years. - A Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics (PK), Pharmacodynamics (PD), PK/PD Characteristics and Safety of Multiple Once-daily Oral Dosing of DPOC-4088 in Healthy Young Male Subjects.